Anti-Integrin Beta 3 (GPIIIa, CD61), PSI Domain [AP-5] Antibody

This IgG1 mouse monoclonal (AP5) was generated human platelet glycoprotein IIIa (GPIIIa; CD61) and is specific for human PSI domain (amino acids 1-6) of glycoprotein IIIa (GPIIIa; CD61) when the integrin is in a complex with RDG containing peptides.

Highlights:

  • Reacts with human glycoprotein IIIa
  • Suitable for Flow Cytometry, Western Blot and Immunohistochemistry applications
  • Has been used by clinical labs to diagnose the rare kidney disease, focal segmental glomerulosclerosis (FSGS)

Glycoprotein IIb/IIIa, also known as integrin aIIbß3 is an integrin complex found on platelets. The complex acts as a receptor for both fibrogen and von Willebrand factor and helps in platelet activation. Defects in glycoprotein IIb/IIIa cause Glanzmann's thrombasthenia, which is an abnormality in the platelets, or bleeding disorder.

From the laboratory of Richard H. Aster, MD, PhD, Blood Center of Wisconsin.

Catalog Number Product DataSheet Size AVAILABILITY Price Qty
EBW107
Anti-Integrin Beta 3 (GPIIIa, CD61), PSI Domain [AP-5] Antibody
100ug In stock
Regular Price:$380.00
On Sale:
Specifications

Product Type: Antibody
Accession ID: P05106
Antigen: Glycoprotein IIIa
Isotype: IgG1
Clonality: Monoclonal
Clone Name: AP5
Reactivity: Human
Species Immunized: Mouse
Epitope: PSI domain (AA1-6)
Purification Method: Protein G
Buffer: PBS, 0.05% (w/v) Sodium azide
Tested Applications: Flow Cytometry (0.01 mg/mL), IHC, WB
Storage: -20C
Shipped: Cold packs

Provider
From the laboratory of Richard H. Aster, MD, PhD, Blood Center of Wisconsin
References
  1. Honda S, Tomiyama Y, Pelletier AJ, Annis D, Honda Y, Orchekowski R, Ruggeri Z, Kunicki TJ. Topography of ligand-induced binding sites, including a novel cation-sensitive epitope (AP5) at the amino terminus, of the human integrin beta 3 subunit. J Biol Chem. 1995 May 19;270(20):11947-54.
  2. Peterson JA, Nelson TN, Kanack AJ, Aster RH. Fine specificity of drug-dependent antibodies reactive with a restricted domain of platelet GPIIIA. Blood. 2008 Feb 1;111(3):1234-9. Epub 2007 Oct 24.
  3. Kekomaki R, Dawson B, McFarland J, Kunicki TJ. Localization of human platelet autoantigens to the cysteine-rich region of glycoprotein IIIa. J Clin Invest. 1991 Sep;88(3):847-54.
  4. Yatuv R, Rosenberg N, Zivelin A, Peretz H, Dardik R, Trakhtenbrot L, Seligsohn U. Identification of a region in glycoprotein IIIa involved in subunit association with glycoprotein IIb: further lessons from Iraqi-Jewish Glanzmann thrombasthenia. Blood. 2001 Aug 15;98(4):1063-9.
  5. Honda S, Tomiyama Y, Pelletier AJ, Annis D, Honda Y, Orchekowski R, Ruggeri Z, Kunicki TJ. Topography of ligand-induced binding sites, including a novel cation-sensitive epitope (AP5) at the amino terminus, of the human integrin beta 3 subunit. J Biol Chem. 1995 May 19;270(20):11947-54.
  6. Pokharel SM, Shil NK, Gc JB, Colburn ZT, Tsai SY, Segovia JA, Chang TH, Bandyopadhyay S, Natesan S, Jones JCR, Bose S. Integrin activation by the lipid molecule 25-hydroxycholesterol induces a proinflammatory response. Nat Commun. 2019 Apr 1;10(1):1482. View Article
  7. Faralli JA, Filla MS, Peters DM. Effect of αvβ3 Integrin Expression and Activity on Intraocular Pressure. Invest Ophthalmol Vis Sci. 2019 Apr 1;60(5):1776-1788. View Article
  8. Chen Y, Ju LA, Zhou F, Liao J, Xue L, Su QP, Jin D, Yuan Y, Lu H, Jackson SP, Zhu C. An integrin α(IIb)β(3) intermediate affinity state mediates biomechanical platelet aggregation. Nat Mater. 2019 Mar 25. View Article
  9. Lang Y, Zhao Y, Zheng C, Lu Y, Wu J, Zhu X, Zhang M, Yang F, Xu X, Shi S, Liu Z. MiR-30 family prevents uPAR-ITGB3 signaling activation through calcineurin-NFATC pathway to protect podocytes. Cell Death Dis. 2019 May 24;10(6):401. View Article
  10. Madhusudhan T, Ghosh S, Wang H, et al. Podocyte Integrin-β3 and Activated Protein C Coordinately Restrict RhoA Signaling and Ameliorate Diabetic Nephropathy. J Am Soc Nephrol. 2020;31(8):1762-1780. View Article

If you publish research with this product, please let us know so we can cite your paper.

Loading...